Evidence map›Paper›PMID 42834940›Full record

ArticleFrontiers in immunology2026

Identification of SARS-CoV-2-specific cytotoxic lymphocytes in cerebrospinal fluid of a patient with cerebral demyelination Post mRNA vaccination.

Takaya Kitano, Masakazu Ishikawa, Makoto Kinoshita, Keigo Kihara, Shuhei Sakakibara, Tomohiro Yata, Ryohei Yamamura, Hideki Mochizuki, Masaru Yokoe, Tatsusada Okuno and 1 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takaya Kitano *Department of Neurology, Toyonaka Municipal Hospital, Osaka, Japan.
Masakazu Ishikawa *Laboratory of Human Immunology (Single Cell Genomics), WPI Immunology Frontier Research Center, the University of Osaka, Osaka, Japan.
Makoto KinoshitaDepartment of Neurology, Graduate School of Medicine, the University of Osaka, Osaka, Japan.
Keigo KiharaDepartment of Neurology, Graduate School of Medicine, the University of Osaka, Osaka, Japan.
Shuhei SakakibaraLaboratory of Immune Regulation, Immunology Frontier Research Center, the University of Osaka, Osaka, Japan.
Tomohiro YataDepartment of Neurology, Graduate School of Medicine, the University of Osaka, Osaka, Japan.
Ryohei YamamuraDepartment of Neurology, Graduate School of Medicine, the University of Osaka, Osaka, Japan.
Hideki MochizukiDepartment of Neurology, Graduate School of Medicine, the University of Osaka, Osaka, Japan.
Masaru YokoeDepartment of Neurology, Toyonaka Municipal Hospital, Osaka, Japan.
Tatsusada OkunoDepartment of Neurology, Graduate School of Medicine, the University of Osaka, Osaka, Japan.
Daisuke OkuzakiLaboratory of Human Immunology (Single Cell Genomics), WPI Immunology Frontier Research Center, the University of Osaka, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Some cerebral demyelinating lesions occur after vaccination. We aimed to elucidate the precise roles of vaccine-activated immune cells and antigen-specific lymphocytes in the central nervous system of a patient who developed cerebral demyelination after vaccination. Methods: Using comprehensive single-cell RNA sequencing and immune repertoire analysis combined with a lymphocyte stimulation assay, we characterized the immunological landscape of a patient who developed right-hand clumsiness after receiving an mRNA vaccine against SARS-CoV-2 and was subsequently diagnosed with tumefactive cerebral demyelination. Results: Natural killer cells and effector CD8+ T cells in the cerebrospinal fluid were more cytotoxic and activated than those in healthy controls. Effector CD8+ T cells specific to SARS-CoV-2 spike peptides were identified in the cerebrospinal fluid. The proportion of these cells in peripheral blood decreased after corticosteroid therapy, in parallel with clinical improvement and a reduction in lesion size. Discussion: Although a direct causal relationship between vaccination and demyelination remains uncertain, our findings suggest that vaccine-activated cytotoxic lymphocytes contribute to immune-mediated demyelinating events in the central nervous system.

Indexed as

COVID-19 VaccinesDemyelinating DiseasesSARS-CoV-2T-Lymphocytes, CytotoxicCD8-Positive T-LymphocytesCOVID-19HumansKiller Cells, NaturalMaleMiddle AgedSpike Glycoprotein, CoronavirusVaccinationCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2demyelinationmultiple sclerosisnatural killer cellsrepertoiresingle cellT cellvaccination

Identifiers

PMID42834940
PMCPMC13634803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.